Imexpharm (STC:IMP) GF Score: 98/100 (As of Jun. 28, 2026) — 10% Above Median


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫42,050.00
GF Value ₫51,706.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm GF Score?

Imexpharm STC:IMP -1.98% 98 GF Score is 98 as of Jun. 28, 2026, which is 10% above its 10-year median of 89.00. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Imexpharm has the GF Score of 98, which implies that the company might have Highest outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 10/10
2. Profitability Rank : 9/10
3. Growth Rank : 10/10
4. GF Value Rank : 9/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Imexpharm might have Highest outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Imexpharm  (STC:IMP) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Imexpharm GF Score Related Terms

STC:IMP vs ZTS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imexpharm GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's GF Score distribution charts can be found below:

* The bar in red indicates where Imexpharm's GF Score falls into.


STC:IMP
98GF Score
Imexpharm Corp STC:IMP
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 98 mean?
Imexpharm (STC:IMP) has a GF Score of 98 as of Jun. 28, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Imexpharm and its competitors. This is 10% above median its historical median of 89.00. Over the past decade, Imexpharm's GF Score has ranged from 63.00 to 97.00.
Is Imexpharm's GF Score too high?
Imexpharm's current GF Score of 98 is 10% above median its 10-year median of 89.00. Over the past 10 years, this metric has ranged from a low of 63.00 to a high of 97.00. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's GF Score compare to ZTS?
Imexpharm's GF Score of 98 can be compared against companies in the Drug Manufacturers industry. Historically, Imexpharm's own GF Score has ranged from 63.00 to 97.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Imexpharm and its competitors. Imexpharm's current GF Score is 98, which is 10% above median its own 10-year median of 89.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,050.00 — trading 18.7% below its estimated fair value. The current GF Score is 98, which is 10% above median its 10-year median of 89.00. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current GF Score is 98 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,050.00 is trading 18.7% below its estimated GF Value™ of ₫51,706.57. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • GF Score: 98 (10% above median its 10-year median of 89.00)
  • GF Value™: ₫51,706.57 vs. price of ₫42,050.00 (18.7% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,050.00
Price
₫51,706.57
GF Value